Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
RANCHO CUCAMONGA, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that a federal jury delivered a unanimous verdict in favor of Amphastar in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. (the "Plaintiffs") in the U.S.
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, will be presenting at the Jefferies Global Healthcare Conference on Tuesday, June 6, 2017 at 10:00 a.m. Eastern Time in New York, NY.
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the 20th Annual Bank of America Merrill Lynch Health Care Conference
RANCHO CUCAMONGA, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 20 th Annual Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16, 2017 at 5:00 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2017
Reports Net Revenues of $56.7 Million for the Three Months Ended March 31, 2017
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2017
RANCHO CUCAMONGA, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2017 ended March 31, 2017, after the market closes on Monday, May 8 th , 2017, and will hold a conference call to discuss
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 12:50 p.m. Eastern Time in New York, NY.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2016
Reports Net Revenues of $63.5 Million for the Three Months Ended December 31, 2016
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 13, 2017
RANCHO CUCAMONGA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2016 ended December 31, 2016, after the market closes on Monday, March 13 th , 2017, and will hold a conference call
View HTML
Toggle Summary Amphastar Announces the Receipt of a CRL for Intranasal Naloxone for the Emergency Treatment of Opioid Overdose
RANCHO CUCAMONGA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced today that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for its New Drug Application ("NDA") for Naloxone Hydrochloride 2mg/0.5mL Nasal
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives Complete Response Letter for PrimateneĀ® Mist
RANCHO CUCAMONGA, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its wholly-owned subsidiary, Armstrong Pharmaceuticals, Inc., for its New Drug
View HTML

 

Copyright Ā©2018 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States